Note 2 - Acquisitions (Details Textual)
$ in Thousands |
|
|
|
3 Months Ended |
|
Aug. 01, 2016
USD ($)
|
Jul. 01, 2016
USD ($)
|
Mar. 14, 2016
USD ($)
|
Sep. 30, 2016
USD ($)
|
Sep. 30, 2015
USD ($)
|
| Zephyrus [Member] | In Process Research and Development, Not Amortizable [Member] |
|
|
|
|
|
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |
|
|
$ 7,400
|
|
|
| Zephyrus [Member] | Developed Technology Rights, Converted from In Process Research and Development [Member] |
|
|
|
|
|
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |
|
|
|
$ 8,300
|
|
| Zephyrus [Member] | Instruments Sales Contingency [Member] |
|
|
|
|
|
| Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High |
|
|
$ 3,500
|
|
|
| Business Combination, Contingent Consideration, Liability, Number of Instruments Sold |
|
|
10
|
|
|
| Business Combination, Contingent Consideration, Liability, Anniversary of Closing Date |
|
|
3 years
|
|
|
| Business Combination, Contingent Consideration, Liability, Cumulative Sales |
|
|
$ 3,000
|
|
|
| Zephyrus [Member] |
|
|
|
|
|
| Payments to Acquire Businesses, Gross |
|
|
8,000
|
|
|
| Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High |
|
|
7,000
|
|
|
| Business Combination, Contingent Consideration, Liability |
|
|
$ 6,900
|
|
|
| Space [Member] |
|
|
|
|
|
| Payments to Acquire Businesses, Gross |
|
$ 9,000
|
|
|
|
| Advanced Cell Diagnostics (ACD) [Member] | The 2016 Revenue Equal or Exceed $30 Milliom [Member] |
|
|
|
|
|
| Business Combination, Contingent Consideration, Liability |
$ 25,000
|
|
|
|
|
| Business Combination, Contingent Consideration, Liability, Trigger Amount of Revenue |
30,000
|
|
|
|
|
| Advanced Cell Diagnostics (ACD) [Member] | The 2017 Revenues Equal or Exceed $45 Million [Member] |
|
|
|
|
|
| Business Combination, Contingent Consideration, Liability |
50,000
|
|
|
|
|
| Business Combination, Contingent Consideration, Liability, Trigger Amount of Revenue |
45,000
|
|
|
|
|
| Advanced Cell Diagnostics (ACD) [Member] | The 2016 Revenue Hurdle Not Met and 2017 Revenue Hurdle Met [Member] |
|
|
|
|
|
| Business Combination, Contingent Consideration, Liability |
25,000
|
|
|
|
|
| Advanced Cell Diagnostics (ACD) [Member] | Trigger a Reduced Earn-Out Payment [Member] | Minimum [Member] |
|
|
|
|
|
| Business Combination, Contingent Consideration, Liability, Trigger Amount of Revenue |
40,000
|
|
|
|
|
| Advanced Cell Diagnostics (ACD) [Member] | Trigger a Reduced Earn-Out Payment [Member] | Maximum [Member] |
|
|
|
|
|
| Business Combination, Contingent Consideration, Liability, Trigger Amount of Revenue |
45,000
|
|
|
|
|
| Advanced Cell Diagnostics (ACD) [Member] | Selling, General and Administrative Expenses [Member] |
|
|
|
|
|
| Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability |
|
|
|
1,900
|
|
| Advanced Cell Diagnostics (ACD) [Member] |
|
|
|
|
|
| Payments to Acquire Businesses, Gross |
250,000
|
|
|
|
|
| Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High |
75,000
|
|
|
|
|
| Business Combination, Contingent Consideration, Liability |
$ 38,200
|
|
|
$ 40,100
|
|
| Developed Technology Rights [Member] |
|
|
|
|
|
| Finite-Lived Intangible Asset, Useful Life |
|
|
|
15 years
|
|
| Trade Names [Member] |
|
|
|
|
|
| Finite-Lived Intangible Asset, Useful Life |
|
|
|
7 years 182 days
|
|
| Customer Relationships [Member] |
|
|
|
|
|
| Finite-Lived Intangible Asset, Useful Life |
|
|
|
10 years
|
|
| Noncompete Agreements [Member] |
|
|
|
|
|
| Finite-Lived Intangible Asset, Useful Life |
|
|
|
2 years
|
|
| Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability |
|
|
|
$ 1,900
|
|